The Human T-Cell Lymphoma/Leukemia Viruses

References

• Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A., Minna J.D., Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl Acad. Sci. USA 1980; 77: 7415–7419
   PubMed Web of Science ®Google Scholar
• Kalyanaraman V.S., Sarngadharan M.G., Robert Guroff M., Miyoski I., Blanynet D., Golde D., Gallo R.C. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982; 218: 571–573
   PubMed Web of Science ®Google Scholar
• Dube S., Doline G., Abbott L., Mehta S., Dube D., Gutierrez S., Ceriani C., Esteban E., Ferrer J., Poiesz B. The complete genomic sequence of a BLV strain from a Holstein cow from Argentina. Virology 2000; 277: 379–386
   PubMed Web of Science ®Google Scholar
• Poiesz B.J., Sherman M., Saksena N., Dube D., Dube S., Gavalchin J., Fan N., Lane M., Paul B. The biology and epidemiology of the human T-cell lymphoma/leukemia viruses. Frontiers of Infectious Diseases: Focus on HIV, H.C. Neu, J. Levy, R. Weiss. Churchill Livingstone, London 1993; 189–205
   Google Scholar
• Digilio L., Gire A., Cho N., Slattery J., Markham P., Franchini G. The simian T-lymphotropic/leukemia virus from Pan paniscus belongs to the type 2 family and infects Asian macaques. J. Virol. 1997; 71: 3684–3692
   PubMed Web of Science ®Google Scholar
• Salemi M., Lewis M., Egan J.F., Hall W.W., Desmyter J., Vandamme A.M. Different population dynamics of human T-cell lymphotropic virus type II in intravenous drug users compared with endemically infected tribes. Proc. Natl Acad. Sci. USA 1999; 13253–13258
   PubMed Web of Science ®Google Scholar
• Dube S., Love J.L., Dube D.K., Leon-Ponte M., Echererria de Perez G., Baroja M.L., Bianco N., Poiesz B.J. The complete genomic sequence of an HTLV-II isolate from a Guahibo Indian from Venezuela. Virology 1999; 253: 181–192
   PubMed Web of Science ®Google Scholar
• Goubau P., Van Brussel M., Vandamme A.M., Liu H.F., Desmyter J. A primate T-lymphotropic virus, PTLV-I, different from human T-lymphotropic viruses type I and II, in a wild-caught baboon (Papio hamadryas). Proc. Natl Acad. Sci. USA 1994; 91: 2848–2852
   PubMed Web of Science ®Google Scholar
• Poiesz B.J., Papsidero L.D., Ehrlich G., Sherman M., Dube S., Poiesz M., Dibbon K., Ruscetti F.W., Slamon D., Fang C., Williams A., Duggan D., Glaser J., Gottlieb A., Goldberg J., Ratner L., Phillips P., Han T., Friedman-Kien A., Siegal F., Rai F., Sawitsky A., Shermata L.W.A., Dosik H., Cunningham C., Montagna R. Prevalence of HTLV-I associated T-cell lymphoma. Am. J. Hematol. 2001; 66: 32–38
   PubMed Web of Science ®Google Scholar
• Poiesz B.J., Dube S., Choi D., Esteban E., Ferrer J., Leon-Pomte M., Echererria de Perez G., Glaser, Derare S.G., Vallari A.S., Schochetman G. Comparative performances of an HTLV-I/II EIA and other serological and PCR assays on samples from persons at risk for HTLV-II infection. Transfusion 2000; 40: 924–930
   PubMed Web of Science ®Google Scholar
• Anderson D.W., Epstein J.S., Lee T.H., Lairmore M.D., Saxinger C., Kalyanaraman V.S., Slamon D., Parks W., Poiesz B.J., Pierik L.T., Lee H., Montagna R., Roche P.A., Williams A., Blattner W. Serological confirmation of human T-lymphotropic virus type I infection in healthy blood and plasma donors. Blood 1989; 74: 2585–2591
   PubMed Web of Science ®Google Scholar
• Lipka J.J., Miyoshi I., Hadlock K.G., Reyes G.R., Chow T.P., Blattner W.A., Shaw G.M., Hanson C.V., Gallo D., Chan L., Foung S.K.H. Segregation of human T cell lymphotropic virus type I and II infections by antibody reactivity to unique viral epitopes. J. Infect. Dis. 1992; 165: 268–272
   PubMed Web of Science ®Google Scholar
• Ehrlich G.D., Glaser J.B., Abbott M.A., Slamon D.J., Keith D., Sliwkowski M., Brandis J., Keitelman E., Teramoto Y., Papsidero L., Simpkins H., Sninsky J.J., Poiesz B.J. Detection of anti-HTLV-I Tax antibodies in HTLV-I enzyme-linked immunosorbent assay-negative individuals. Blood 1989; 74: 1066–1072
   PubMed Web of Science ®Google Scholar
• Duggan D.B., Ehrlich G., Davey F.P., Davey F.P., Kwok S., Sninsky J., Goldberg J., Baltrucki L., Poiesz B.J. HTLV-I induced lymphoma mimicking Hodgkin's disease: diagnosis by polymerase chain reaction amplification of specific HTLV-I sequences in tumor DNA. Blood 1988; 74: 1027–1032
   Google Scholar
• Hall W.W., Liu C.R., Schneewind O., Takahashi H., Kaplan M.H., Roupe G., Vahlne A. Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science 1991; 253: 317–320
   PubMed Web of Science ®Google Scholar
• Dyster L.M., Abbott L., Bryz-Gornia V., Poiesz B.J., Papsidero L. Microplate-based DNA hybridization assays for the detection of human retroviral gene sequences. J. Clin. Micriobiol. 1994; 32: 547–550
   Web of Science ®Google Scholar
• Poiesz B., Dube S., Jones B., Bryz-Gornia V., Dean M.T., Spicer T., Hengst J., Sayre K., Esteban E., Ferrer J.F. Comparative performances of enzyme-linked immunosorbent, Western blot, and polymerase chain reaction assays for human T-lymphotropic virus type II infection that is endemic among Indians of the Gran Chaco region of South America. Transfusion 1997; 37: 52–59
   PubMed Web of Science ®Google Scholar
• Dube D.K., Dube S., Erensoy S., Jones B., Bryz-Gornia V., Spicer T., Love J., Saksena N., Lechat M.F., Shrager D.I., Dosik H., Glasner J., Lewis W., Blattner W., Montagna R., Blumberg B.S., Poiesz B.J. Serological and nucleic acid analyses for HIV and HTLV infection on archival human plasma samples from Zaire. Virology 1994; 202: 379–389
   PubMed Web of Science ®Google Scholar
• Sherman M.P., Dube S., Dube D., Poiesz B.J. Virally induced T-cell malignancies and associated diseases. Clinical Immunology: Principles and Practice, C.R.A. Rich. Mosby-Year Book, St. Louis 1995
   Google Scholar
• Weiss R.A., Clapham P., Nagy K., Hoshino H. Envelope properties of human T-cell leukemia viruses. Curr. Top. Microbiol. Immunol. 1985; 115: 235–246
   PubMed Web of Science ®Google Scholar
• Kirchbaum-Stenger K., Poiesz B.J., Ehrlich G., Gavalchin J., Davis B.H., Moore J. Specific adsorption of HTLV-I to various target human and animal cells. Blood 1987; 70: 1303–1311
   PubMed Web of Science ®Google Scholar
• Gavalchin J., Fan N., Lane M.J., Papsidero L., Poiesz B.J. Identification of a putative cellular receptor for HTLV-I by a monoclonal antibody, Mab 34-23. Virology 1994; 194: 1–9
   Web of Science ®Google Scholar
• Sagara Y., Ishida C., Inoue Y., Shiraki H., Maeda Y. 71-kilodalton heat shock cognate protein acts as a cellular receptor for syncytium formation induced by human T-cell lymphotropic virus type 1. J. Virol. 1998; 72: 535–541
   PubMed Web of Science ®Google Scholar
• Gavalchin J., Fan N., Waterbury P., Corbett E., Faldasz B.D., Peshick S., Poiesz B.J., Papsidero L., Lane M.J. Regional localization of the putative cell surface receptor for HTLV-I to human chromosome 17q23.2–17q25.3. Virology 1995; 212: 196–203
   PubMed Web of Science ®Google Scholar
• Yoshida M. Tenth anniversary perspectives on AIDS. Host-HTLV type I interaction at the molecular level. AIDS Res. Hum. Retroviruses 1994; 10: 1193–1197
   PubMed Web of Science ®Google Scholar
• Fan N., Gavalchin J., Paul B., Wells T.H., Lane M.J., Poiesz B.J. Infection of peripheral blood mononuclear cells and cell lines by cell free human T-cell lymphoma/leukemia virus type I. J. Clin. Microbiol. 1992; 30: 905–910
   PubMed Web of Science ®Google Scholar
• Preston B.D., Poiesz B.J., Loeb L.A. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242: 1168–1171
   PubMed Web of Science ®Google Scholar
• Temin H.M. Retrovirus variation and reverse transcription: abnormal strand transfers result in retrovirus genetic variation. Proc. Natl Acad. Sci. USA 1993; 90: 6900–6903
   PubMed Web of Science ®Google Scholar
• Seiki M., Hattori S., Hirayami Y., Yoshida M. Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc. Natl Acad. Sci. USA 1983; 80: 3618–3622
   PubMed Web of Science ®Google Scholar
• Shimotohno K., Takahashi Y., Shimizu N., Gojobori T., Golde D.W., Chen I.S., Miwa M., Sugimura T. Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: an open reading frame for the protease gene. Proc. Natl Acad. Sci. USA 1985; 82: 3101–3105
   PubMed Web of Science ®Google Scholar
• Sodroski J.G., Rosen C.A., Haseltine W.A. Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells. Science 1984; 225: 381–385
   PubMed Web of Science ®Google Scholar
• Felber B.K., Paskalis H., Kleinman-Ewing C., Wong-Staal F., Pavlakis G.N. The pX protein of HTLV-I is a transcriptional activator of its long terminal repeats. Science 1985; 229: 675–679
   PubMed Web of Science ®Google Scholar
• Shimotohno K., Takano M., Teruuchi T., Miwa M. Requirements of multiple copies of a 21-nucleotide sequence in the U3 region of human T-cell leukemia virus type I and type II long terminal repeats for trans-acting activation of transcription. Proc. Natl Acad. Sci. USA 1986; 83: 8112–8116
   PubMed Web of Science ®Google Scholar
• Dube S., Paul B., Bryz-Gornia V., Stephens C., Erensoy S., Dube D.K., Poiesz B.J. Use of PCR in detection of antisense transcripts in HTLV-I-infected patients and human T-cell lines. Methods in Neuroscience's, G. Sarkar. Academic Press, New York 1995; Vol. 26: 381–400
   Google Scholar
• Rosenblatt J.D., Cann A.J., Slamon D.J., Smallberg I.S., Shah N.P., Fujii J., Wachsman W.J., Chelna I.S.Y. HTLV-II transcription is regulated by the overlapping tax/rex nonstructural genes. Science 1988; 240: 916–919
   PubMed Web of Science ®Google Scholar
• Rimsky L., Dodon M.D., Dixon E.P., Greene W.C. Trans-dominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator. Nature 1989; 341: 453–456
   PubMed Web of Science ®Google Scholar
• Watanbe C.T., Rosenblatt J.D., Bakker A., Morgan J.P., Lizo J., Chun S., Black A.C. Negative regulation of gene expression from the HTLV-II long terminal repeat by Rex: functional and structural dissociation from positive posttranscriptional regulation. AIDS Res. Hum. Retroviruses 1996; 12: 535–546
   PubMed Web of Science ®Google Scholar
• Hidaka M., Inoue J., Yoshida M., Seiki M. Post-transcriptional regulator (rex) of HTLV-1 initiates expression of viral structural proteins but suppresses expression of regulatory proteins. E.M.B.O. J. 1998; 7: 519–523
   Google Scholar
• Graziano S.L., Lehr B., Merl S.A., Moor J.L., Hallinan E.J., Hubbel C., Davis B., Poiesz B.J. A quantitative assay for HTLV-I transformation. Cancer Res. 1987; 47: 2468–2473
   PubMed Web of Science ®Google Scholar
• Hiscott J., Beauparlant P., Crepieux P., DeLuca C., Kwon H., Lin R., Petropoulos L. Cellular and viral protein interactions regulating I kappa B alpha activity during human retrovirus infection. J. Leukoc. Biol. 1997; 62: 82–92
   PubMed Web of Science ®Google Scholar
• Li X.K., Murphy K.M., Palka K.T., Surabhi R.M., Gaynor R.B. The human T-cell leukemia virus type-1 Tax protein regulates the activity of the IkB kinase complex. J. Biol. Chem. 1999; 274: 34417
   PubMed Web of Science ®Google Scholar
• Petropoulos L., Lin R., Hiscott J. Human T cell leukemia virus type 1 tax protein increases NF-kappa B dimer formation and antagonizes the inhibitory activity of the I kappa B alpha protein. Virology 1996; 225: 52–64
   PubMed Web of Science ®Google Scholar
• Judd B.A., Koretzky G.A. Antigen specific T lymphocyte activation. Rev. Immunogenet. 2000; 2: 164–174
   PubMedGoogle Scholar
• Schwartz R.H. T-cell clonal anergy. Curr. Opin. Immunol. 1997; 9: 351–357
   PubMed Web of Science ®Google Scholar
• Good L., Maggirwar S.B., Harhaj E.W., Sun S.C. Constitutive dephosphorylation and activation of a member of the nuclear factor of activated T cells, NF-AT1, in Tax-expressing and type I human T-cell leukemia virus-infected human T cells. J. Biol. Chem. 1997; 272: 1425–1428
   PubMed Web of Science ®Google Scholar
• Good L., Maggirwar S.B., Sun S.C. Activation of the IL-2 gene promoter by HTLV-I tax involves induction of NF-AT complexes bound to the CD28-responsive element. E.M.B.O. J. 1996; 15: 3744–3750
   PubMed Web of Science ®Google Scholar
• Fujii M., Iwai K., Oie M., Fukushi M., Yamamoto N., Kannagi M., Mori N. Activation of oncogenic transcription factor AP-1 in T cells infected with human T cell leukemia virus type 1. AIDS Res. Hum. Retroviruses 2000; 16: 1603–1606
   PubMed Web of Science ®Google Scholar
• Iwai K., Mori N., Oie M., Yamamoto N., Fujii M. Human T-cell leukemia virus type 1 tax protein activates transcription through AP-1 site by inducing DNA binding activity in T cells. Virology 2001; 279: 38–46
   PubMed Web of Science ®Google Scholar
• Leonard W.J., O'Shea J.J. Jaks and STATs: biological implications. Annu. Rev. Immunol. 1990; 16: 293–322
   Google Scholar
• Sugamura K., Fujii M., Sakitani M., Kobayashi N., Nakai S., Hatanaka M., Hinuma Y. Human retrovirus-induced IL-2 receptors and their possible role in transduction of continuous cell growth signal. Princess Takamatsu Symp. 1984; 15: 269–276
   PubMedGoogle Scholar
• Uchiyama T., Wano Y., Tsudo M., Umadome H., Hori T., Tamori S., Uchino H., Yodoi J., Maeda M., Kobayashi N., et al. Abnormal expression of interleukin-2 receptor (Tac antigen) in adult T-cell leukemia. Princess Takamatsu Symp. 1984; 15: 253–258
   PubMedGoogle Scholar
• Himes S.R., Katsikeros R., Shannon M.F. Costimulation of cytokine gene expression in T cells by the human T leukemia/lymphotropic virus type 1 trans activator Tax. J. Virol. 1996; 70: 4001–4008
   PubMed Web of Science ®Google Scholar
• Nakamura N., Fujii M., Tsukahara T., Arai M., Ohashi T., Wakao H., Kannagi M., Yamamoto N. Human T-cell leukemia virus type 1 Tax protein induces the expression of STAT1 and STAT5 genes in T-cells. Oncogene 1999; 18: 2667–2675
   PubMed Web of Science ®Google Scholar
• Arima N. Autonomous and interleukin-2-responsive growth of leukemic cells in adult T-cell leukemia (ATL): a review of the clinical significance and molecular basis of ATL cell growth. Leuk. Lymphoma 1997; 26: 479–487
   PubMed Web of Science ®Google Scholar
• Hollsberg P., Wucherpfennig K.W., Ausubel L.J., Calvo V., Bierer B.E., Hafler D.A. Characterization of HTLV-I in vivo infected T cell clones. IL-2-independent growth of nontransformed T cells. J. Immunol. 1992; 148: 3256–3263
   PubMed Web of Science ®Google Scholar
• Akagi T., Shimotohno K. Proliferative response of Tax1-transduced primary human T cells to anti-CD3 antibody stimulation by an interleukin-2-independent pathway. J. Virol. 1993; 67: 1211–1217
   PubMed Web of Science ®Google Scholar
• Yang Y.C., Hung T.P., Wang C.H., Lin M.T., Hsu T.Y., Chen J.Y., Chen Y.C., Yang C.S. Establishment and characterization of an HTLV-I cell line from a Taiwanese patient with HTLV-I-associated myelopathy. J. Neurol. Sci. 1993; 120: 46–53
   PubMed Web of Science ®Google Scholar
• Zhang Q., Lee B., Koreck M., Li G., Weyland C., Eck S., Gessain A., Arima N., Lessin S.R., Shaw L.M., Luger S., Kamoun M., Wasik M.A. Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+) IL-2-independent and IL-2-dependant cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia. Leukemia Res. 1999; 23: 373–384
   PubMed Web of Science ®Google Scholar
• Stiegler P., Kasten M., Giordano A. The RB family of cell cycle regulatory factors. J. Cell Biochem. Suppl. 1998; 30–31: 30–36
   PubMedGoogle Scholar
• Ewen M.E., Miller S.J. p53 and translational control. Biochim. Biophys. Acta 1996; 1242: 181–184
   PubMed Web of Science ®Google Scholar
• Wang X.W., Harris C.C. p53 tumor-suppressor gene: clues to molecular carcinogenesis. J. Cell Physiol. 1997; 173: 247–255
   PubMed Web of Science ®Google Scholar
• Shapiro G.I., Edwards C.D., Rollins B.J. The physiology of p16 (INK4A)-mediated G1 proliferative arrest. Cell Biochem. Biophys. 2000; 33: 189–197
   PubMed Web of Science ®Google Scholar
• Suzuki T., Kitao S., Matsushime H., Yoshida M. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16-ink4a and counteracts its inhibitory activity towards CDK4. Leukemia 1997; 11(Suppl 3)14–16
   PubMedGoogle Scholar
• Suzuki T., Narita T., Uchida-Toita M., Yoshida M. Down-regulation of the INK4 family of cyclin-dependent kinase inhibitors by tax protein of HTLV-1 through two distinct mechanisms. Virology 1999; 259: 384–391
   PubMed Web of Science ®Google Scholar
• Yin M.J., Gaynor R.B. HTLV-1 21 bp repeat sequences facilitate stable association between Tax and CREB to increase CREB binding affinity. J. Mol. Biol. 1996; 264: 20–31
   PubMed Web of Science ®Google Scholar
• Harrod R., Tang Y., Nicot C., Lu H.S., Vassilev A., Nakatani Y., Giam C.Z. An exposed KID-like domain in human T-cell lymphotropic virus type 1 Tax is responsible for the recruitment of coactivators CBP/p300. Mol. Cell. Biol. 1998; 18: 5052–5061
   PubMed Web of Science ®Google Scholar
• Suzuki T., Uchida-Toita M., Yoshida M. Tax protein of HTLV-1 inhibits CBP/p300-mediated transcription by interfering with recruitment of CBP/p300 onto DNA element of E-box or p53 binding site. Oncogene 1999; 18: 4137–4143
   PubMed Web of Science ®Google Scholar
• Van Orden K., Giebler H.A., Lemasson I., Gonzales M., Nyborg J.K. Binding of p53 to the KIX domain of CREB binding protein. A potential link to human T-cell leukemia virus, type I-associated leukemogenesis. J. Biol. Chem. 1999; 274: 26321–26328
   PubMed Web of Science ®Google Scholar
• Ariumi Y., Kaida A., Lin J.Y., Hirota M., Masui O., Yamaoka S., Taya Y., Shimotohno K. HTLV-1 tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration. Oncogene 2000; 19: 1491–1499
   PubMed Web of Science ®Google Scholar
• Scoggin K.E.S., Ulloa A., Nyborg J.K. The oncoprotein Tax binds the SRC-1-interacting domain of CBP/p300 to mediate transcriptional activation. Mol. Cell. Biol. 2001; 21: 5520–5530
   PubMed Web of Science ®Google Scholar
• Robeck M.D., Ratner L. Immortalization of T-lymphocytes by human T-cell leukemia virus type 1 is independent of the Tax-CBP/p300 interaction. J. Virol. 2000; 74: 11988–11992
   PubMed Web of Science ®Google Scholar
• Wong B., Choi Y. Pathways leading to cell death in T-cells. Curr. Opin. Immunol. 1997; 9: 358–364
   PubMed Web of Science ®Google Scholar
• Baker S.J., Reddy E.P. Modulation of life and death by the TNF receptor superfamily. Oncogene 1998; 17: 3261–3270
   PubMed Web of Science ®Google Scholar
• Chao D.T., Korsmeyer S.J. BCL-2 family: regulators of cell death. Annu. Rev. Immunol. 1998; 16: 395–419
   PubMed Web of Science ®Google Scholar
• Malek N.P., Pluempe J., Kubicka S., Manns M.P., Trautwein C. Molecular mechanisms of TNF receptor-mediated signaling. Recent Results Cancer Res. 1998; 147: 97–106
   PubMedGoogle Scholar
• Scaffidi C., Kirchhoff S., Krammer P.H., Peter M.E. Apoptosis signaling in lymphocytes. Curr. Opin. Immunol. 1999; 11: 277–285
   PubMed Web of Science ®Google Scholar
• Screaton G., Xu X.N. T cell life and death signaling via TNF-receptor family members. Curr. Opin. Immunol. 2000; 12: 316–322
   PubMed Web of Science ®Google Scholar
• Kawakami A., Nakashima T., Sakai H., Urayama S., Yamasaki S., Hida A., Tsuboi M., Nakamura H., Ida H., Migita K., Kawabe Y., Eguchi K. Inhibition of caspase cascade by HTLV-I tax through induction of NF-kappa B nuclear translocation. Blood 1999; 94: 3847–3854
   PubMed Web of Science ®Google Scholar
• Brauweiler A., Garrus J.E., Reed J.C., Nyborg J.K. Repression of bax gene expression by the HTLV-1 Tax protein: implications for suppression of apoptosis in virally infected cells. Virology 1997; 231: 135–140
   PubMed Web of Science ®Google Scholar
• Tsukahara T., Kannagi M., Ohashi T., Kato H., Arai M., Nunez G., Iwanaga Y., Yamamoto N., Ohtani K., Nakamura M., Fujii M. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-kappa B in apoptosis-resistant T-cell transfectants with Tax. J. Virol. 1999; 73: 7981–7987
   PubMed Web of Science ®Google Scholar
• Miyake H., Suzuki T., Hirai H., Yoshida M. Trans-activator Tax of human T-cell leukemia virus type 1 enhances mutation frequency of the cellular genome. Virology 1999; 253: 155–161
   PubMed Web of Science ®Google Scholar
• Philpott S.M., Buehring G.C. Defective DNA repair in cells with human T-cell leukemia/bovine leukemia viruses: role of tax gene. J. Natl Cancer Inst. 1999; 91: 933–942
   PubMed Web of Science ®Google Scholar
• Kao S.Y., Marriott S.J. Disruption of nucleotide excision repair by the human T-cell leukemia virus type 1 Tax protein. J. Virol. 1999; 73: 4299–4304
   PubMed Web of Science ®Google Scholar
• Kelman Z. PCNA: structure, functions and interactions. Oncogene 1997; 14: 629–640
   PubMed Web of Science ®Google Scholar
• Wood R.D., Shivji M.K. Which DNA polymerases are used for DNA-repair in eukaryotes?. Carcinogenesis 1997; 18: 605–610
   PubMed Web of Science ®Google Scholar
• Saggioro D., Majone F., Forino M., Turchetto L., Leszl A., Chieco-Bianchi L. Tax protein of human T-lymphotropic virus type I triggers DNA damage. Leuk. Lymphoma 1994; 12: 281–286
   PubMed Web of Science ®Google Scholar
• Waga S., Hannon G.J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574–578
   PubMed Web of Science ®Google Scholar
• Jeang K.T., Widen S.G., Semmes O.J., 4th. Wilson SH: HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. Science 1990; 247: 1082–1084
   PubMed Web of Science ®Google Scholar
• Teshigawara K., Maeda M., Nishino K., Nikaido T., Uchiyama T., Tsudo M., Wano Y., Yodoi J. Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression. J. Mol. Cell Immunol. 1985; 2: 17–26
   PubMedGoogle Scholar
• Tagaya Y., Maeda Y., Mitsui A., Konodo N., Matsui H., Hamuro J., Brown N., Arai K., Yokota T., Wakasugi H., Yodoi J. ATL-derived factor (ADF), an IL-2 receptor/Tac-inducer homologous to thioredoxin; possible involvement of dithiol reduction in the IL-2 receptor induction. E.M.B.O. J. 1989; 8: 757–764
   PubMed Web of Science ®Google Scholar
• Laurent T.C., Moore E.C., Reichard P. Enzymatic synthesis of deoxyribonucleotides. IV. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J. Biol. Chem. 1964; 239: 3436–3436
   PubMed Web of Science ®Google Scholar
• Yodoi J., Tursz T. ADF, a growth-promoting factor derived from adult T cell leukemia and homologous to thioredoxin: involvement in lymphocyte immortalization by HTLV-I and EBV. Adv. Cancer. Res. 1991; 57: 381–411
   PubMed Web of Science ®Google Scholar
• Abate C., Patel L., Rauscher F.J., 3rd, Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science 1990; 249: 1157–1161
   PubMed Web of Science ®Google Scholar
• Xanthoudakis S., Curran T. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. E.M.B.O. J. 1992; 11: 653–665
   PubMed Web of Science ®Google Scholar
• Seki S., Akiyama K., Watanabe S., Hatsushika M., Ikeda S., Tsutsui K. cDNA and deduced amino acid sequence of a mouse DNA repair enzyme (APEX nuclease) with significant homology to Escherichia coli exonuclease III. J. Biol. Chem. 1991; 266: 20797–20802
   PubMed Web of Science ®Google Scholar
• Matthews J.R., Wakasugi N., Virelizier J.L., Yodoi J., Hay R.T. Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulfide bond involving cysteine 62. Nucleic Acids Res. 1992; 20: 3821–3830
   PubMed Web of Science ®Google Scholar
• Matsuda M., Masutani H., Nakamura H., Miyajima S., Yamauchi A., Yonehara S., Uchida A., Irimajiri K., Horiuchi A., Yodoi J. Protective activity of adult T cell leukemia-derived factor (ADF) against necrosis factor-dependent cytotoxicity on U937 cells. J. Immunol. 1991; 147: 3837–3841
   PubMed Web of Science ®Google Scholar
• Nakamura H., Matsuda M., Furuke K., Kitaoka Y., Iwata S., Toda K., Inamoto T., Yamaoka Y., Ozawa K., Yodoi J. Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2cell injury caused by activated neutrophils or hydrogen. Immunol. Lett. 1994; 42: 75–80
   PubMed Web of Science ®Google Scholar
• Schenk H., Vogt M., Droge W., Schulze-Osthoff K. Thioredoxin as a potent costimulus of cytokine expression. J. Immunol. 1996; 156: 765–771
   PubMed Web of Science ®Google Scholar
• Manns A., Hanchard B., Morgan O.S., Wilks R., Cranston B., Nam J.M., Blank M., Kuwayama M., Yashiki S., Fujiyoshi T., Blattner W., Sonoda S. Human leukocyte antigen class II alleles associated with human T-cell lymphotropic virus type I infection and adult T-cell leukemia/lymphoma in a Black population. J. Natl Cancer Inst. 1998; 90: 617–622
   PubMed Web of Science ®Google Scholar
• White J.D., Johnson J.A., Nam J.M., Cranston B., Hanchard B., Waldmann T.A., Manns A. Distribution of human leukocyte antigens in a population of black patients with human T-cell lymphotrophic virus type I-associated adult T-cell leukemia/lymphoma. Cancer Epidemiol. Biomarkers Prev. 1996; 5: 873–877
   PubMed Web of Science ®Google Scholar
• Hanabuchi S., Ohashi T., Koya Y., Kato H., Takemura F., Hirokawa K., Yoshiki T., Yagita H., Okumura K., Kannagi M. Development of human T-cell leukemia virus type 1-transformed tumors in rats following suppression of T-cell immunity by CD80 and CD86 blockade. J. Virol. 2000; 74: 428–435
   PubMed Web of Science ®Google Scholar
• Ohashi T., Hanabuchi S., Kato H., Koya Y., Takemura F., Hirokawa K., Yoshiki T., Tanaka Y., Fujii M., Kannagi M. Induction of adult T-cell leukemia-like lymphoproliferative disease and its inhibition by adoptive immunotherapy in T-cell-deficient nude rats inoculated with syngeneic human T-cell leukemia virus type 1-immortalized cells. J. Virol. 1999; 73: 6031–6040
   PubMed Web of Science ®Google Scholar
• Ibuki K., Funahashi S.I., Yamamoto H., Nakamura M., Igarashi T., Miura T., Ido E., Hayami M., Shida H. Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene. J. Gen. Virol. 1997; 78: 147–152
   PubMed Web of Science ®Google Scholar
• Jinnohara T., Tsujisaki M., Sasaki S., Hinoda Y., Imai K. Cytotoxic activity in a case of adult T-cell leukemia/lymphoma with spontaneous regression. Int. J. Hematol. 1997; 65: 293–298
   PubMed Web of Science ®Google Scholar
• Matsushita K., Arima N., Fujiwara H., Hidaka S., Ohtsubo H., Arimura K., Kukita T., Okamura M., Tei C. Spontaneous regression associated with apoptosis in a patient with acute-type adult T-cell leukemia. Am. J. Hematol. 1999; 61: 144–148
   PubMed Web of Science ®Google Scholar
• Mitsuya H., Matis L.A., Megson M., Bunn P.A., Murray C., Mann D.L., Gallo R.C., Broder S. Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus. J. Exp. Med. 1983; 158: 994–999
   PubMed Web of Science ®Google Scholar
• Kannagi M., Sugamura K., Kinoshita K., Uchino H., Hinuma Y. Specific cytolysis of fresh tumor cells by an autologous killer T cell line derived from an adult T cell leukemia/lymphoma patient. J. Immunol. 1984; 133: 1037–1041
   PubMed Web of Science ®Google Scholar
• Jacobson S., Shida H., McFarlin D.E., Fauci A.S., Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 1990; 348: 245–248
   PubMed Web of Science ®Google Scholar
• Kannagi M., Matsushita S., Harada S. Expression of the target antigen for cyto-toxic T lymphocytes on adult T-cell-leukemia cells. Int. J. Cancer 1993; 54: 582–588
   PubMed Web of Science ®Google Scholar
• Astier-Gin T., Portail J.P., Londos-Gagliardi D., Moynet D., Blanchard S., Dalibart R., Pouliquen J.F., Georges-Courbot M.C., Hajjar C., Sainte-Foie S., Guillemain B. Neutralizing activity and antibody reactivity toward immunogenic regions of the human T cell leukemia virus type I surface glycoprotein in sera of infected patients with different clinical states. J. Infect. Dis. 1997; 175: 716–719
   PubMed Web of Science ®Google Scholar
• Tendler C.L., Burton J.D., Jaffe J., Danielpour D., Charley M., McLoy J.P., Pittelkow M.R., Waldmann T.A. Abnormal cytokine expression in Sezary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies. Cancer Res. 1994; 54: 4430–4435
   PubMed Web of Science ®Google Scholar
• Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia/lymphoma: a report from the lymphoma study group (1984–87). Br. J. Hematol. 1991; 79: 428–437
   PubMed Web of Science ®Google Scholar
• Bunn P.A., Jr., Schecter G.P., Jaffe E., Blayney D., Young R.C., Matthews M.J., Blattner W., Broder S., Robert-Guroff M., Gallo R.C. Clinical course of retrovirus associated adult T-cell lymphoma in the United States. N. Engl. J. Med. 1983; 309: 257–264
   PubMed Web of Science ®Google Scholar
• Shimoyama M., Ota K., Kikuchi M., Yunoki K., Konda S., Takatsuki K., Ichimaru M., Ogawa M., Kimura I., Tominaga S., Tsugane S., Taguchi H., Minato K., Takenaka T., Tobinai K., Kurita S., Oyama A., Hisano S., Kozuru M., Matsumoto M., Nomura K., Takiguchi T., Susumu S., Yamaguchi K., Hattori T., Kinoshita K., Tajima K., Suemasu K. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J. Clin. Oncol. 1988; 6: 128–141
   PubMed Web of Science ®Google Scholar
• Shimoyama M. Treatment of patients with adult T-cell leukemia-lymphoma: and overview. Gann Monogr. Cancer Res. 1992; 39: 43–43
   Google Scholar
• Hanada S., Utsunomiya A., Suzuki S., Uozumi K., Makino T., Arima T. Treatment for adult T-cell leukemia. Cancer Chemother. Pharmacol. 1997; 40(Suppl)S47–S50
   PubMed Web of Science ®Google Scholar
• Kojima H., Hori M., Shibuya A., Nagasawa T., Miwa M., Abe T. Successful treatment of a patient with adult T-cell leukemia by daily oral administration of low-dose etoposide. Decrease in the amount of HTLV-I proviral DNA revealed by the polymerase chain reaction method. Cancer 1993; 72: 3614–3617
   PubMed Web of Science ®Google Scholar
• Tsuda H., Takatsuki K., Ohno R., Masaoka T., Okada K., Shirakawa S., Ohashi Y., Ota K. Treatment of adult T-cell leukaemia–lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy. Br. J. Cancer 1994; 70: 771–774
   PubMed Web of Science ®Google Scholar
• Ikeda K., Oka M., Yamada Y., Soda H., Fukuda M., Kinoshita A., Tsukamoto K., Noguchi Y., Isomoto H., Takeshima F., Murase K., Kamihira S., Tomonaga M., Kohno S. Adult T-cell leukemia cells over-express the multidrug-resistance-protein (MRP) and lung-resistance-protein (LRP) genes. Int. J. Cancer 1999; 82: 599–604
   PubMed Web of Science ®Google Scholar
• Loe D.W., Deeley R.G., Cole S.P. Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer 1996; 32: 945–957
   Google Scholar
• Borg A., Yin J.A.L., Johnson P.E., Tosswill J., Saunders M., Morris D. Successful treatment of HTLV-1-associated adult T-cell leukemia lymphoma by allogenic bone marrow transplantation. Br. J. Hematol. 1996; 94: 713–715
   PubMed Web of Science ®Google Scholar
• Tamura K., Makino S., Araki Y., Imamura T., Seita M. Recombinant interferon-β and gamma in the treatment of adult T-cell leukemia. Cancer 1987; 59: 1059–1062
   PubMed Web of Science ®Google Scholar
• Gill P.S., Harrington; W., Jr., Kaplan M.H., Kibcero R.C., Bennett J.M., Lieberman H.A., Bernstein-Sanger M., Espena B.M., Cabral L., Allen S., Komblau S., Pike M.C., Levine A. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N. Engl. J. Med. 1995; 332: 1744–1748
   PubMed Web of Science ®Google Scholar
• Bazarbachi A., Nasr R., El-Sabban M.E., Mahe A., Mahieux R., Gessain A., Darwiche N., Dbaibo G., Kersual J., Zermati Y., Dianoux L., Chelbi-Alix M.K., de The H., Hermine O. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia 2000; 14: 716–721
   PubMed Web of Science ®Google Scholar
• Bazarbachi A., El-Sabban M.E., Nasr R., Quignon F., Awaraji C., Kersual J., Dianoux L., Zermati Y., Haidar J.H., Hermine O., de The H. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999; 93: 278–283
   PubMed Web of Science ®Google Scholar
• Li H.C., Yashiki S., Sonoda J., Lou H., Ghosh S.K., Byrnes J.J., Lema C., Fujiyoshi T., Karasuyama M., Sonoda S. Green tea polyphenols induce apoptosis in vitro in peripheral blood T lymphocytes of adult T-cell leukemia patients. Jpn. J. Cancer Res. 2000; 91: 34–40
   PubMedGoogle Scholar
• Okamura T., Shibuya T., Harada M., Niho Y. Successful treatment of chronic adult T-cell leukemia with ubenimex. Acta Haematol. 1992; 87: 94–97
   PubMed Web of Science ®Google Scholar
• Waldmann T.A., White J.D., Goldman C.K., Top L., Grant A., Bamford R., Roessler E., Horak I.D., Zaknoen S., Kasten-Sportes C., England R., Horak E., Mishra B., Dipre M., Hales P., Fleisher T., Junghans R.P., Jaffe E.S., Nelson D.L. The interleukin-2 receptor: a target for monoclonal antibody treatment of T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 1993; 82: 1701–1712
   PubMed Web of Science ®Google Scholar
• Waldmann T.A. The promiscuous IL-2/IL-15 receptor: a target for immunotherapy of HTLV-I-associated disorders. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996; 13(Suppl 1)S179–S185
   PubMedGoogle Scholar
• Kreitman R.J., Schneider W.P., Queen C., Tsudo M., Fitzgerald D.J., Waldmann T.A., Pastan I. Mik-beta 1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the beta-chain of the IL-2 receptor. J. Immunol. 1992; 149: 2810–2815
   PubMed Web of Science ®Google Scholar
• Kreitman R.J., Chaudhary V.K., Waldmann T.A., Hanchard B., Cranston B., FitzGerald D.J., Pastan I. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia 1993; 7: 553–562
   PubMed Web of Science ®Google Scholar
• Waldmann T.A., White J.D., Carrasquillo J.A., Reynolds J.C., Paik C.H., Gansow O.A., Brechbiel M.W., Jaffe E.S., Fleisher T.A., Goldman C.K., Top L.E., Bamford R., Zaknoen S., Roessler E., Kasten-Sportes C., England R., Litou H., Johnson J.A., Jackson-White T., Manns A., Hanchard B., Junghans R.P., Nelson D.L. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia withYttrium-90-labeled anti-Tac. Blood 1995; 86: 4063–4075
   PubMed Web of Science ®Google Scholar
• Nichols J., Foss F., Kuzel T.M., LeMaistre C.F., Platanias L., Ratain M.J., Rook A., Saleh M., Schwartz G. Interleukin-2 fusion protein: and investigational therapy for interleukin-2 receptor expressing malignancies. Eur. J. Cancer 1997; 33(Suppl.)S34–S36
   PubMedGoogle Scholar
• Ferrer J.F., Esteban E., Dube S., Basombrio M.A., Segovia A., Peralta-Ramos M., Dube D.K., Sayre K., Aguayo N., Hengst J., Poiesz B.J. Endemic infection with the human T lymphotropic virus type II B in Argentinean and Paraguayan Indians. Distribution by ethnicity and molecular characterization. J. Inf. Dis. 1996; 174: 944–953
   PubMed Web of Science ®Google Scholar
• Love J., Marchiole C.C., Dube S., Bryz-Gornia V., Loughran T.P., Jr., Glaser J.B., Esteban E., Feldman L., Ferrer J.F., Poiesz B.J. Expansion of clonotypic T-cell populations in the peripheral blood of asymptomatic Gran Chaco Amerindians infected with HTLV-IIB. J. AIDS Hum. Retroviruses 1998; 18: 178–185
   PubMedGoogle Scholar
• Rosenblatt J.D., Giorgie J.V., Golde D.W., Ezra J.B., Wu A., Winberg C.D., Glaspy J., Wachsman W., Chen I.S. Integrated human T-cell leukemia virus II genome in CD8+ T-cells from a patient with “atypical” hairy cell leukemia: evidence for distinct T- and B-cell lymphoproliferative disorders. Blood 1988; 71: 363–369
   PubMed Web of Science ®Google Scholar
• Loughran T.P., Jr., Coyle T., Sherman M., Starkebaum G., Ehrlich G.D., Ruscetti F.W., Poiesz B.J. Detection of human T-cell leukemia/lymphoma virus type II in a patient with LGL leukemia. Blood 1992; 80: 1116–1119
   PubMed Web of Science ®Google Scholar
• Loughran T.P. Hr., Sherman M.P., Ruscetti F.W., Frey S., Coyle T., Montagna R.A., Jones B., Starkebaum G., Poiesz B.J. Prototypical HTLV-I/II infection is rare in LGL leukemia. Leuk. Res. 1994; 18: 423–429
   PubMed Web of Science ®Google Scholar
• Ehrlich G., Glaser J., La Vigne K., Quan D., Mildvan D., Sninsky J., Kwok S., Papsidero L., Poiesz B. Prevalence of human T-cell leukemia/lymphoma virus type II infection among high-risk individuals: type specific identification of HTLV's by polymerase chain reaction. Blood 1989; 74: 1658–1664
   PubMed Web of Science ®Google Scholar
• Kaplan M.H., Hall W.W., Susin M., Pahwa S., Salahuddin S.Z., Heilman C., Fetten J., Coronesi M., Farber B.F., Smith S. Syndrome of severe skin disease, eosinophilia, and dermatopathic lymphadenopathy in patients with HTLV-II complicating human immunodeficiency virus infection. Am. J. Med. 1991; 91: 300–309
   PubMed Web of Science ®Google Scholar
• Poiesz B., Dube D., Dube S., Love J., Papsidero L., Uner A., Hutchinson R. HTLV-II-associated cutaneous T-cell lymphoma in a patient with HIV-I infection. N. Engl. J. Med. 2000; 342: 930–936
   PubMed Web of Science ®Google Scholar
• Bhagavati S., Ehrlich G., Kula R., Kwok S., Sninsky J., Udani V., Poiesz B.J. Detection of human T-cell lymphoma/leukemia virus type I (HTLV-I) in the spinal fluid and blood of cases of chronic progressive myelopathy and a clinical radiological and electrophysiological profile of HTLV-I associated myelopathy. N. Engl. J. Med. 1988; 318: 1141–1147
   PubMed Web of Science ®Google Scholar
• Kitajima I., Yamamoto K., Sato K., Nakajima Y., Nakajima T., Maruyama I., Osame M., Nishioka K. Detection of human T-cell lymphotropic virus type I expression in synovial cells in chronic inflammatory arthropathy. J. Clin. Investig. 1991; 88: 1315–1322
   PubMed Web of Science ®Google Scholar
• Mochizuki M., Watanabe T., Yamaguchi K., Takatsuki K., Yoshimura K., Shirao M., Nakashima S., Mori S., Araki S., Miyata N. HTLV-I uveitis: a distinct clinical entity caused by HTLV-I. Jpn. J. Cancer Res. 1992; 83: 236–239
   PubMedGoogle Scholar
• Harrington W.J., Jr., Ucar A., Gill P., Snodgrass S., Sheremata W., Cabral L., Rabin M., Byrne G.E., Jr., Berger J., Voight W., Kemper R., Miller G., Whitcomb C.C., Greenberg A., Byrnes J.J., Poiesz B.J. Clinical spectrum of HTLV-I in South Florida. J. AIDS Hum. Retroviruses 1995; 8: 466–473
   PubMedGoogle Scholar
• Harrington W.J., Sheremata W.A., Snodgraa S.R., Denension S., Berger S., Jr. Tropical spastic paraparesis/HTLV-I associated myelopathy (TSP/HAM): treatment with an anabolic steroid danazol. AIDS Res. Hum. Retroviruses 1991; 7: 1031–1034
   PubMed Web of Science ®Google Scholar
• Harrington W.J., Jr., Sheremata W., Hjille B., Dube D.K., Bradshaw P., Foung S.K., Snodgrass S., Toedter G., Cabral L., Poiesz B. Spastic ataxia associated with human T-cell lymphotropic virus type II infection. Ann. Neurol. 1993; 33: 411–414
   PubMed Web of Science ®Google Scholar
• Castillo L.C., Gracia F., Roman G.C., Levine P., Reeves W.C., Kaplan J. Spinocerebellar syndrome in patients infected with human T-lymphotropic virus types I and II (HTLV-I/HTLV-II): report of 3 cases from Panama. Acta. Neurol. Scand. 2000; 101: 405–412
   PubMed Web of Science ®Google Scholar